ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.40) by 30 percent. The company reported quarterly sales of $18.464 million which beat the analyst consensus estimate of $18.462 million by 0.01 percent. This is a 27.40 percent increase over sales of $14.493 million the same period last year.